<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Haemonetics Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/haemonetics-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(VPHM) Update on ViroPharma Industrial Facility</title>
		<link>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534</link>
		<comments>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:55:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[PAS]]></category>
		<category><![CDATA[PepsiAmericas Inc.]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91534</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Cinryze’s industrial scale manufacturing facility. The regulatory body made three comments related to a portion of the cleaning validation for industrial scale manufacturing, of which only one requires additional unplanned activity. ViroPharma does not expect this activity to take much time to complete. The FDA also said that it has not finished reviewing the company’s January 2012 updated responses to observations specific to the September 2011 inspection of the Amsterdam facility. We note that ViroPharma undertook an expansion of the production capacity for Cinryze in 2009. In early 2010, the company submitted the Cinryze industrial scale manufacturing Prior Approval Supplement (PAS) to the FDA. In October 2010, the regulatory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma  Drug Earns Priority Review</title>
		<link>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265</link>
		<comments>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265#comments</comments>
		<pubDate>Mon, 16 Jan 2012 23:37:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90265</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s approval for the treatment of prevention, pre-procedure prevention, and treatment of attacks of hereditary angioedema (HAE) in patients who are six years or older. The company expects Health Canada to complete its review of Cinryze in the second half of 2012. We note that Cinryze is currently marketed in the US for the prevention of angioedema attacks in adolescent and adult patients with HAE. In the European Union (EU), the same drug is marketed for the treatment of prevention, pre-procedure prevention, and treatment of attacks of HAE in adolescents and adult patients. We view this development as a positive for ViroPharma, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Going Strong</title>
		<link>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191</link>
		<comments>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:37:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86191</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted third quarter 2011 earnings (including special items) of 35 cents per share, surpassing the Zacks Consensus Estimate of 33 cents, but lower than the year-ago figure of 45 cents. Excluding special items, but including stock based compensation expense, earnings came in at 52 cents per share for the third quarter, reflecting an increase of 8.3%. Higher revenues and lower share count helped boost earnings. Revenues Higher sales from Cinryze helped improve quarterly revenues to $143.0 million, from $117.8 million reported in the year-ago quarter. Revenues also beat the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 33.2% to $65.4 million during the reported quarter, and Vancocin sales came in at $76.6 million, reflecting an increase of 13.3%. While the increase in Cinryze sales was due ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma and Halozyme Therapeutics Begin Trial</title>
		<link>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259</link>
		<comments>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259#comments</comments>
		<pubDate>Mon, 19 Sep 2011 20:40:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83259</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) and its partner Halozyme Therapeutics (HALO) recently announced the initiation of a mid-stage trial on its drug Cinryze. The phase II study is designed to evaluate the safety, and pharmacokinetics and pharmacodynamics of the subcutaneous formulation of Cinryze in combination with Halozyme&#8217;s Enhanze technology, in patients suffering from hereditary angioedema (HAE). Cinryze in the intravenous form is currently marketed worldwide as a treatment for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. The Enhanze technology is a proprietary drug-delivery platform, using Halozyme&#8217;s recombinant human hyaluronidase enzyme (rHuPH20). This proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin. The initiation of the trial triggered a milestone payment of $3 million from ViroPharma to Halozyme. This ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses</title>
		<link>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406</link>
		<comments>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80406</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted second quarter fiscal 2011 earnings of 36 cents per share, missing the Zacks Consensus Estimate by 3 cents and the year-ago figure by a penny. Despite higher revenues, earnings bore the brunt of increased operating expenses. Revenues Higher sales from Cinryze boosted the quarterly revenues from $109.0 million in the year-ago quarter to $128.8 million. However, revenues fell shy of the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 55.1% to $62.5 million during the reported quarter, while Vancocin sales came in at $65.2 million, reflecting a slide of 4.7%. The increase in Cinryze sales was due to higher patient demand. On the other hand, Vancocin sales were negatively impacted by declining volume, partly offset by price rise. Other Details Research and development (R&#38;D) expenses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Company News for August 2, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405</link>
		<comments>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405#comments</comments>
		<pubDate>Tue, 02 Aug 2011 21:23:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[KEG]]></category>
		<category><![CDATA[Key Energy Services Inc]]></category>
		<category><![CDATA[Old National BanCorporation]]></category>
		<category><![CDATA[ONB]]></category>
		<category><![CDATA[PAET]]></category>
		<category><![CDATA[PAETEC Holding Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80405</guid>
		<description><![CDATA[•    Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion, exceeding the Zacks Consensus Estimate of $6.91 billion•    Auxilium Pharmaceuticals (NASDAQ:AUXL) posted a Q2 loss of $0.11 per share, less than the analysts&#8217; estimate for a loss of $0.19 per share. Revenues for the quarter increased 30.5% year-over-year to $65.9 million •    Humana (NYSE:HUM) reported Q2 EPS of $2.50, beating the Zacks Consensus Estimate of $2.07 per share. Revenues increased 8.1% year-over-year to $9.28 billion, lower than the Zacks Consensus Estimate of $9.32 billion •    Acorda Therapeutics (NASDAQ:ACOR) posted Q2 EPS of $0.01. Revenues for the pharma company rose 52.6% year-over-year to $65.3 million •    Share prices of Old National ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/02/acor-company-news-for-august-2-2011-corporate-summary/80405/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CHMP) ViroPharma&#8217;s Epilepsy Drug Recommended</title>
		<link>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702</link>
		<comments>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702#comments</comments>
		<pubDate>Tue, 28 Jun 2011 20:02:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77702</guid>
		<description><![CDATA[The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently gave the go ahead to ViroPharma Inc.’s (VPHM) Buccolam (midazolam, oromucosal solution). The company is seeking approval for Buccolam to be used as a treatment for prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years. The European Commission’s (EC) decision on ViroPharma’s Pediatric Use Marketing Authorization (PUMA) for Buccolam is expected by the fourth quarter of 2011, which will also make the candidate the first product to gain approval under the centralized PUMA procedure. PUMA is a new type of centralized marketing authorization procedure for medicines that are developed specifically for children and may already be approved for other indications or routes of administration in adults. ViroPharma’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire to Produce More Replagal</title>
		<link>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664</link>
		<comments>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664#comments</comments>
		<pubDate>Tue, 28 Jun 2011 15:54:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HGT]]></category>
		<category><![CDATA[Hugoton Royalty Trust]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77664</guid>
		<description><![CDATA[UK-based Shire (SHPGY) recently announced that the European Medicines Agency (EMA) has increased the company’s manufacturing flexibility for Replagal (agalsidase alfa), an enzyme replacement therapy approved for treating Fabry disease. The EMA declared that Replagal can be purified at its new manufacturing facility located in Lexington. The European approval for the new manufacturing facility for Replagal was sought by Shire in April 2011. The approval grants Shire, the global market leader for the treatment of Fabry disease, an additional manufacturing facility to purify the product. Prior to the approval, Replagal was purified only at the company’s facility in Alewife, Cambridge. The increased manufacturing strength will enable Shire meet the huge demand for treating the disease in a more efficient manner. Shire’s Replagal competes with Sanofi-Aventis’ (SNY) Fabrazyme in the market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire&#8217;s Firazyr Earns FDA Panel Backing</title>
		<link>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456</link>
		<comments>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:48:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77456</guid>
		<description><![CDATA[Recently, the Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and recommended the US approval of Shire’s (SHPGY) Firazyr (icatibant). Shire is looking to get Firazyr approved in the US for treating patients (aged 18 years and above) suffering from acute attacks of hereditary angioedema (HAE). HAE is a rare genetic disease characterized by acute swelling of the hands, feet, face and larynx. The FDA panel was convinced of Firazyr’s safety and effectiveness based on data from three double-blind, randomized late-stage studies (FAST-1, FAST-2, and FAST-3). Twelve of the 13 members of the panel recommended the approval of the drug for the indication. Moreover, 11 of the 13 members (one member voted against the motion while the other panel member abstained from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179</link>
		<comments>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:09:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77179</guid>
		<description><![CDATA[A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices industry continues to grow at a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma&#8217;s HAE Drug Gets EU Nod</title>
		<link>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542</link>
		<comments>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:20:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76542</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the European Commission (EC) granted Centralized Marketing Authorization to Cinryze for the treatment of hereditary angioedema (HAE). The drug is indicated for the treatment of pre-procedure prevention of angioedema attacks in adults and adolescents with HAE, and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment. The EC’s approval of Cinryze does not come as a surprise, as in March the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended it. We note that in May, ViroPharma had entered into a global licensing deal with Halozyme Therapeutics, Inc. (HALO), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics to Discuss Plans</title>
		<link>http://www.stockbloghub.com/2011/04/13/hae-haemonetics-to-discuss-plans/71354</link>
		<comments>http://www.stockbloghub.com/2011/04/13/hae-haemonetics-to-discuss-plans/71354#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:13:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71354</guid>
		<description><![CDATA[Haemonetics (HAE) will hold its annual investor and analyst day on May 12, 2011 at its corporate headquarters in Braintree, Massachusetts. Other than guidance for fiscal 2012, the company will discuss issues such as the Plasma market scenario, status of IMPACT’s sales and an update on the various R&#38;D initiatives. Haemonetics earns about 82% of its revenues from the sale of disposables – plasma disposables, blood bank disposables and hospital disposables. Of these divisions, the maximum contribution comes from plasma disposables. However, for the past few quarters this segment has been witnessing some challenges. Average weekly shipments of plasma disposables in the last reported quarter (third quarter of fiscal 2011) were up 17% from the average daily shipments in the fourth quarter of fiscal 2010, which was the lower end ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/hae-haemonetics-to-discuss-plans/71354/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Industry Outlook &#8211; April 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413</link>
		<comments>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413#comments</comments>
		<pubDate>Thu, 31 Mar 2011 23:07:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70413</guid>
		<description><![CDATA[Last year was challenging for medical device companies given the exigent economic conditions and an uncertain healthcare environment. The MedTech industry was hit by several macro headwinds in 2010 including price/volume and utilization pressure and a more restrictive regulatory environment. Although a number of these issues remain, the industry is expected to fare better this year due to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest medical devices market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (“HCIT”). The U.S. medical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Industry Outlook December 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/12/06/mdt-medical-devices-industry-outlook-december-2010-industry-outlook/61379</link>
		<comments>http://www.stockbloghub.com/2010/12/06/mdt-medical-devices-industry-outlook-december-2010-industry-outlook/61379#comments</comments>
		<pubDate>Tue, 07 Dec 2010 01:15:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=61379</guid>
		<description><![CDATA[Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative with 2009 worldwide sales in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (“HCIT”). The U.S. medical devices industry continues to grow at a brisk rate, thanks to an aging Baby Boomer population, high unmet medical needs and increased incidence of lifestyle diseases (including cardiovascular diseases, diabetes, hypertension and obesity). Neuro, Orthopedic and Aesthetic represent the fastest growing categories. The aging population represents a major catalyst for demand of medical devices. The elderly population (persons 65 years and above) base in the U.S. registered 39.6 million in 2009, representing roughly 13% of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/06/mdt-medical-devices-industry-outlook-december-2010-industry-outlook/61379/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CMS) Medical Devices Industry Outlook &#8211; August 2010 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/08/25/cms-medical-devices-industry-outlook-august-2010-zacks-analyst-interviews/49243</link>
		<comments>http://www.stockbloghub.com/2010/08/25/cms-medical-devices-industry-outlook-august-2010-zacks-analyst-interviews/49243#comments</comments>
		<pubDate>Wed, 25 Aug 2010 15:14:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Utilities]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49243</guid>
		<description><![CDATA[Prelude The global medical devices industry is fairly large, intensely competitive and highly innovative with annual worldwide sales in 2009 in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (HCIT). The U.S. medical devices industry continues to grow at a brisk rate, thanks to an aging Baby Boomer population, with Neuro, Orthopedic and Aesthetic representing the fastest growing categories. With several growth constraints in the legacy markets, medical devices companies are aiming to expand into lucrative incipient markets. Expansion in the emerging markets, especially those with double-digit annual growth rates, represents one of the best potential avenues for future growth. Our focus in this write up, however, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/25/cms-medical-devices-industry-outlook-august-2010-zacks-analyst-interviews/49243/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CMS) Medical Devices Industry Outlook &#8211; August 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/08/24/cms-medical-devices-industry-outlook-august-2010-industry-outlook/49231</link>
		<comments>http://www.stockbloghub.com/2010/08/24/cms-medical-devices-industry-outlook-august-2010-industry-outlook/49231#comments</comments>
		<pubDate>Tue, 24 Aug 2010 22:53:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Utilities]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49231</guid>
		<description><![CDATA[Prelude The global medical devices industry is fairly large, intensely competitive and highly innovative with annual worldwide sales in 2009 in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (HCIT). The U.S. medical devices industry continues to grow at a brisk rate, thanks to an aging Baby Boomer population, with Neuro, Orthopedic and Aesthetic representing the fastest growing categories. With several growth constraints in the legacy markets, medical devices companies are aiming to expand into lucrative incipient markets. Expansion in the emerging markets, especially those with double-digit annual growth rates, represents one of the best potential avenues for future growth. Our focus in this write up, however, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/24/cms-medical-devices-industry-outlook-august-2010-industry-outlook/49231/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Review &#8211; May 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750</link>
		<comments>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750#comments</comments>
		<pubDate>Tue, 11 May 2010 21:55:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36750</guid>
		<description><![CDATA[The global medical devices industry is fairly large, with annual worldwide sales in 2009 in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc. We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles. Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy. We advise investors to avoid companies that have grown historically through ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Wins New Customer Nassau University Medical Center</title>
		<link>http://www.stockbloghub.com/2010/04/18/masi-masimo-wins-new-customer-nassau-university-medical-center/34100</link>
		<comments>http://www.stockbloghub.com/2010/04/18/masi-masimo-wins-new-customer-nassau-university-medical-center/34100#comments</comments>
		<pubDate>Mon, 19 Apr 2010 01:40:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34100</guid>
		<description><![CDATA[Masimo Corp. (MASI) recently reported that its new customer, Nassau University Medical Center (NUMC), has completed its system-wide conversion to Masimo SET pulse oximetry technology. The conversion allows clinicians to monitor NUMC patients non-invasively using the latest pulse oximetry technology. This in turn provides real time data for vital parameters that aid clinicians in faster and accurate patient treatments. Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple blood constituents that previously required invasive procedures. The multiple blood constituents measured are total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), oxyhemoglobin (SpO2), methemoglobin (SpMet), acoustic respiration rate (RRa), pulse rate (PR), and perfusion index (PI), etc. Masimo SET pulse oximetry eliminates the need to draw blood and wait for results. This helps physicians to immediately detect and treat ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/18/masi-masimo-wins-new-customer-nassau-university-medical-center/34100/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Enters New Agreement</title>
		<link>http://www.stockbloghub.com/2010/03/25/hae-haemonetics-enters-new-agreement/31559</link>
		<comments>http://www.stockbloghub.com/2010/03/25/hae-haemonetics-enters-new-agreement/31559#comments</comments>
		<pubDate>Thu, 25 Mar 2010 19:39:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31559</guid>
		<description><![CDATA[Haemonetics Corp. (HAE) recently entered a new reagent development and supply agreement with Quotient Biodiagnostics Group and its wholly-owned subsidiary Alba Bioscience Limited. Per the agreement, Haemonetics will have exclusive access to Alba&#8217;s comprehensive catalogue of approved reagents for use in connection with the commercialization of its Arryx laser based blood typing platform. The agreement includes future milestone payments related to the optimization of reagents for use in the Arryx system. Haemonetics will have a perpetual license for exclusive access to Alba’s reagents for commercialization. The new agreement represents a significant opportunity for Haemonetics to tap the estimated $1 billion blood typing market. Haemonetics is the market leader in developing and manufacturing blood collection and processing technology. The agreement facilitates and accelerates the development of the Arryx platform for Haemonetics ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/hae-haemonetics-enters-new-agreement/31559/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Analysts Maintain Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/03/17/masi-masimo-analysts-maintain-neutral-rating/30936</link>
		<comments>http://www.stockbloghub.com/2010/03/17/masi-masimo-analysts-maintain-neutral-rating/30936#comments</comments>
		<pubDate>Wed, 17 Mar 2010 19:33:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30936</guid>
		<description><![CDATA[We continue to maintain our ‘Neutral’ rating on Masimo Corp. (MASI) with a target price of $28 based on a P/E of 28.0x our fiscal 2010 EPS estimate of $1. The company’s fourth quarter fiscal 2009 results reflect a mixed trend. Masimo reported fourth-quarter earnings per share of 23 cents, surpassing the Zacks Consensus Estimate of 22 cents. However, earnings was lower than the year-ago figure of 24 cents. For fiscal 2009, earnings per share was 88 cents, in line with the Zacks Consensus Estimate and higher than 78 cents, a year-ago. Total revenue in the fourth quarter increased 11% year over year to $92.6 million. Product revenue increased 12% year over year to $80.5 million. Royalty revenue increased 6% year over year to $12.2 million. Growth in product revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/17/masi-masimo-analysts-maintain-neutral-rating/30936/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Receives U.S. Food and Drug Administration Approval</title>
		<link>http://www.stockbloghub.com/2010/02/28/hae-haemonetics-receives-u-s-food-and-drug-administration-approval/28981</link>
		<comments>http://www.stockbloghub.com/2010/02/28/hae-haemonetics-receives-u-s-food-and-drug-administration-approval/28981#comments</comments>
		<pubDate>Mon, 01 Mar 2010 04:40:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28981</guid>
		<description><![CDATA[Haemonetics Corp. (HAE) recently received the U.S. Food and Drug Administration (FDA) approval for its expanded nomogram to collect two Red Blood Cells on the Cymbal Automated Blood Collection System from female donors. The donors are identified as those who weigh at least 150 pounds and measure 63 inches in height. Cymbal is a battery operated instrument that automates blood collection from volunteer donors. This improves process control and helps alleviate blood shortages. We think that the new approval will expand Haemonetics’ customer base and fuel its top-line growth. It has been estimated that the FDA approval will expand utilization of the Cymbal technology by 3-6% among female donors. Haemonetics recently reported third quarter fiscal 2010 results. Earnings per share was 71 cents, compared to the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/28/hae-haemonetics-receives-u-s-food-and-drug-administration-approval/28981/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Corporation Misses Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/02/hae-haemonetics-corporation-misses-earnings-estimates/26806</link>
		<comments>http://www.stockbloghub.com/2010/02/02/hae-haemonetics-corporation-misses-earnings-estimates/26806#comments</comments>
		<pubDate>Wed, 03 Feb 2010 01:19:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26806</guid>
		<description><![CDATA[Haemonetics Corporation (HAE) reported third quarter fiscal 2010 earnings per share of 71 cents, missing the Zacks Consensus Estimate of 72 cents. Earnings in the year-ago quarter were 63 cents. The earnings estimate revision for Haemonetics has demonstrated a downtrend in the past 30 days. During the period, one out of twelve analysts has downgraded his earnings estimate for the fourth quarter of fiscal 2010 and full fiscal 2010. However, there were no earnings downgrades for fiscal 2011. Haemonetics has witnessed earnings surprises in all the preceding four quarters varying between 3.17% and 6.15%, with the four-quarter average being 4.69%. In both the first and second quarter, Haemonetics beat the Zacks Consensus Estimate by 6.15%. Sales Total sales in the third quarter increased 6.3% year over year to $165.2 million. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/02/hae-haemonetics-corporation-misses-earnings-estimates/26806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDRX) Medical Devices Stock Review &#8211; Feburary 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636</link>
		<comments>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636#comments</comments>
		<pubDate>Mon, 01 Feb 2010 22:23:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Hanger Orthopedic Group Inc.]]></category>
		<category><![CDATA[HGR]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26636</guid>
		<description><![CDATA[The global medical devices industry is fairly large, with annual worldwide sales in excess of $200 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc. We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles. Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy. Another area which is interestingly poised for growth these days is Healthcare IT. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation Announces Positive Results From Clinical Study</title>
		<link>http://www.stockbloghub.com/2010/01/25/masi-masimo-corporation-announces-positive-results-from-clinical-study/25894</link>
		<comments>http://www.stockbloghub.com/2010/01/25/masi-masimo-corporation-announces-positive-results-from-clinical-study/25894#comments</comments>
		<pubDate>Mon, 25 Jan 2010 20:30:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25894</guid>
		<description><![CDATA[Masimo Corporation (MASI) recently announced positive results form its 21-month clinical study on the impact of the Masimo Patient SafetyNet remote monitoring and clinician notification system. Results indicated that continuous pulse oximetry monitoring and clinician notification in post-surgical patients on the general floor leads to a significant drop in key clinical outcome measures, such as 65% fewer rescue events, 48% fewer ICU transfers and reduced annualized ICU time by 135 days. Masimo Patient SafetyNet combines the performance of Masimo SET pulse oximetry at the point of care with remote monitoring and wireless clinician notification via pager. This is the first study on adults using Masimo SET pulse oximetry technology that demonstrated improved patient safety while reducing the cost. Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/25/masi-masimo-corporation-announces-positive-results-from-clinical-study/25894/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KERX) Healthcare Stock Watch: Short List of Booming (and Busting) Companies</title>
		<link>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406</link>
		<comments>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406#comments</comments>
		<pubDate>Wed, 20 Jan 2010 18:11:08 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[QCOR]]></category>
		<category><![CDATA[Questcor Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25406</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 20, 2010: Issue #1179 On my way out to San Francisco last week, I never thought that I’d compare the biggest healthcare conference of the year to the dating scene. But that’s the overall vibe that I took away from the JP Morgan Healthcare Conference. The investors I spoke with reminded me of jilted lovers – eager to get back on the market, but scared to get hurt again. Rather than checking out the eligible candidates on Match.com, though, healthcare investors spend their time poring over companies’ balance sheets and drug pipelines. And so it was in San Francisco. Everyone wanted to be optimistic, but that optimism was only expressed in private conversations. When I saw the same investors in front of companies’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation Can Now Earn While Patients Test Device Effectiveness</title>
		<link>http://www.stockbloghub.com/2010/01/05/masi-masimo-corporation-can-now-earn-while-patients-test-device-effectiveness/24122</link>
		<comments>http://www.stockbloghub.com/2010/01/05/masi-masimo-corporation-can-now-earn-while-patients-test-device-effectiveness/24122#comments</comments>
		<pubDate>Tue, 05 Jan 2010 18:29:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24122</guid>
		<description><![CDATA[Masimo Corporation (MASI) has recently received a new Current Procedural Terminology (CPT) code from the American Medical Association, 88738, for its noninvasive hemoglobin (SpHb) measurement. Medicare has priced the new CPT code at $7.19 on its 2010 Medicare Clinical Laboratory Fee Schedule. The new pricing has been effective since Jan 1, 2010. The new CPT code is an important milestone for Masimo. It will now permit health care providers to bill and receive payments from Medicare when testing eligible patients. This in turn will encourage them to use Masimo’s SpHb measurement  devices that will expand the company’s top line. Masimo develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/masi-masimo-corporation-can-now-earn-while-patients-test-device-effectiveness/24122/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Files Patent Infringement Lawsuit Against Fenwal Inc</title>
		<link>http://www.stockbloghub.com/2009/12/15/hae-haemonetics-files-patent-infringement-lawsuit-against-fenwal-inc/22900</link>
		<comments>http://www.stockbloghub.com/2009/12/15/hae-haemonetics-files-patent-infringement-lawsuit-against-fenwal-inc/22900#comments</comments>
		<pubDate>Wed, 16 Dec 2009 05:29:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22900</guid>
		<description><![CDATA[Haemonetics Corporation (HAE) has recently filed a new lawsuit against Fenwal Inc. regarding the latter’s continued patent infringement with the release of its red cell collection kits. Fenwal allegedly modified its separation chamber to bypass Haemonetics’ patent. The court has issued an injunction prohibiting Fenwal from continuing to sell these infringed products after Dec 1, 2010. The tussle between Haemonetics and Fenwal began early this year when a federal jury determined that Fenwal&#8217;s original collection kit infringes a Haemonetics patent and found Fenwal liable for payment of damages of over $15 million to Haemonetics. The United States District Court for the District of Massachusetts later ordered the product to be removed from the market by Dec 1, 2010. The court also ordered Fenwal to pay a 10% royalty based on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/15/hae-haemonetics-files-patent-infringement-lawsuit-against-fenwal-inc/22900/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Completes Conversion of New Customer</title>
		<link>http://www.stockbloghub.com/2009/12/14/masi-masimo-completes-conversion-of-new-customer/22770</link>
		<comments>http://www.stockbloghub.com/2009/12/14/masi-masimo-completes-conversion-of-new-customer/22770#comments</comments>
		<pubDate>Tue, 15 Dec 2009 01:30:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22770</guid>
		<description><![CDATA[Masimo Corp. (MASI) reported that its new customer, Brookdale University Hospital and Medical Center in Brooklyn, New York, has completed its system-wide conversion to Masimo SET pulse oximetry technology. Brookdale has also installed Masimo’s first-ever continuous and noninvasive hemoglobin monitoring (SpHb) technology in its select care settings. This allows clinicians to detect and treat chronic or acute anemia earlier, more effectively manage blood transfusions for their patients and identify internal bleeding quicker. The Brookdale University Hospital and Medical Center is one of the largest voluntary nonprofit teaching hospitals in Brooklyn and a New York State Department of Health (DOH) designated Stroke Center. Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple blood constituents that previously required invasive procedures. The multiple blood constituents measured are total hemoglobin (SpHb), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/14/masi-masimo-completes-conversion-of-new-customer/22770/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation Earns FDA New Product Approval</title>
		<link>http://www.stockbloghub.com/2009/12/02/masi-masimo-corporation-earns-fda-new-product-approval/21799</link>
		<comments>http://www.stockbloghub.com/2009/12/02/masi-masimo-corporation-earns-fda-new-product-approval/21799#comments</comments>
		<pubDate>Wed, 02 Dec 2009 22:21:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21799</guid>
		<description><![CDATA[Masimo Corporation (MASI) recently received the U.S. Food and Drug Administration (FDA) approval for its new product, Masimo Rainbow SET Acoustic Monitoring. The new product enables noninvasive and continuous monitoring of human respiration rate (RRa). The data provided is accurate, easy-to-use, and thereby enhances patient compliance. With the approval, Masimo expects to launch the product in a limited market release in the U.S. in this month. The new product enables earlier detection of respiratory compromise and patient distress. This is especially important for post-surgical patients receiving patient-controlled analgesia for pain management. It is seen that these patients often suffer from respiratory problems due to sedation, which can result in serious injury or even death. Masimo Rainbow SET Acoustic Monitoring also eliminates the lack of accuracy and patient compliance issues prevalent ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/masi-masimo-corporation-earns-fda-new-product-approval/21799/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation Renews Deal with Advocate Health Care</title>
		<link>http://www.stockbloghub.com/2009/11/29/masi-masimo-corporation-renews-deal-with-advocate-health-care/21455</link>
		<comments>http://www.stockbloghub.com/2009/11/29/masi-masimo-corporation-renews-deal-with-advocate-health-care/21455#comments</comments>
		<pubDate>Mon, 30 Nov 2009 04:25:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21455</guid>
		<description><![CDATA[Masimo Corporation (MASI) announced that one of its prominent customers, Advocate Health Care, has recently renewed its multi-year, system-wide contract for Masimo SET pulse oximetry technology. Advocate Health Care is Illinois&#8217; largest and one of the top ten health care providers in the U.S. It has more than 200 patient-care sites across Chicago. Financial terms of the contract have not been disclosed. Advocate Health Care has been Masimo’s customer since 2001. The contract enables Masimo to support the pulse oximetry needs of more than 200 sites of Advocate Health Care. This will in turn boost Masimo’s top-line. Masimo Corporation develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/29/masi-masimo-corporation-renews-deal-with-advocate-health-care/21455/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Corporation Enters Agreement with Masimo</title>
		<link>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535</link>
		<comments>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:12:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20535</guid>
		<description><![CDATA[CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise. CareFusion’s ventilators and infusion pumps facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions by accessing total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and PVI for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate. CareFusion is a medical technology company formed recently by the spin-off of the Clinical and Medical Products business ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Corporation Reports Strong Earnings Results</title>
		<link>http://www.stockbloghub.com/2009/11/04/hae-haemonetics-corporation-reports-strong-earnings-results/19590</link>
		<comments>http://www.stockbloghub.com/2009/11/04/hae-haemonetics-corporation-reports-strong-earnings-results/19590#comments</comments>
		<pubDate>Wed, 04 Nov 2009 21:15:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19590</guid>
		<description><![CDATA[Haemonetics Corporation (HAE) reported strong results for the second quarter of fiscal 2010. Earnings per share were 69 cents, beating the Zacks Consensus Estimate of 65 cents and the year-ago earnings of 58 cents. Sales Total revenues in the reported quarter were $157 million Incorporatedreasing 8% year over year. Excluding a favorable foreign currency translation (FX), revenues increased 6% year over year. On a geographic basis, U.S. sales represented roughly 48% of total sales and increased 12.5% year over year. International sales increased 3.5% year over year. Plasma disposables revenues increased 19% year over year to $59 million. Growth can be attributed to higher global demand for plasma collections, higher pricing and implementation of several long-term contracts with customers in the reported quarter. Platelet disposables revenues increased 3% year over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/04/hae-haemonetics-corporation-reports-strong-earnings-results/19590/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDRX) Medical Devices &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/10/16/mdrx-medical-devices-industry-outlook/17835</link>
		<comments>http://www.stockbloghub.com/2009/10/16/mdrx-medical-devices-industry-outlook/17835#comments</comments>
		<pubDate>Fri, 16 Oct 2009 20:38:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Dickinson And Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Hanger Orthopedic Group Inc.]]></category>
		<category><![CDATA[HGR]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17835</guid>
		<description><![CDATA[The global medical devices industry is fairly large and is valued at roughly $223 billion, with the U.S. accounting for approximately 41%. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT. In the medical devices space, we recommend that investors focus on companies providing life-sustaining products. These companies provide a strong recurring stream of revenues as patients are unable to forego these products. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles. Large companies with a wide portfolio of products are also better poised for good returns. These companies are capable of withstanding the current economic recession. Another area which is interestingly poised for growth these days is Healthcare IT. The landscape has changed since the Obama Administration passed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/mdrx-medical-devices-industry-outlook/17835/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

